CONTEXT: Reproductive hormones are incompletely characterized during the menopause transition (MT). HYPOTHESIS: Increased anovulation and decreased progesterone accompany progress through the MT. DESIGN: The Daily Hormone Study (DHS) of the Study of Women's Health Across the Nation (SWAN) included 848 women aged 43-53 yr at baseline who collected daily urine for one cycle or up to 50 d annually for 3 yr. MAIN OUTCOME MEASURES: LH, FSH, estrone conjugates, and pregnanediol glucuronide levels were assessed. Cycles were classified by presumed luteal (ovulatory) status and bleeding. Hormones were related to time in study, age, menopausal status, and selected variables. RESULTS: Ovulatory-appearing cycles declined from 80.9% at baseline to 64.7% by the third assessment (H3). Cycles presumed anovulatory and not ending with bleeding by 50 d (anovulatory/nonbleeding) increased from 8.4 to 24% by H3 and were associated with progress to early perimenopause [odds ratio (OR) = 2.66; confidence interval (CI) = 1.17-6.04] or late perimenopause (OR = 56.21; CI = 18.79-168.12; P < 0.0001), African-American ethnicity (OR = 1.91; CI = 1.06-3.43), and less than high school education (OR = 3.51; CI = 1.62-7.62). Anovulatory cycles ending with bleeding remained at about 10% from baseline to H3; compared with ovulatory cycles, they were associated with obesity (OR = 4.68; CI = 1.33-16.52) and more than high school education (OR = 2.12; CI = 1.22-3.69; P = 0.02). Serum estradiol in both the highest and lowest categories was associated with anovulatory/nonbleeding collections. Pregnanediol glucuronide decreased 6.6% for each year on study. Insulin sensitivity measures did not relate strongly to menstrual cycle hormones. CONCLUSIONS: Anovulation without bleeding represents progression of the MT. A small but detectable decrease in luteal progesterone excretion occurs as women progress through the MT.
CONTEXT: Reproductive hormones are incompletely characterized during the menopause transition (MT). HYPOTHESIS: Increased anovulation and decreased progesterone accompany progress through the MT. DESIGN: The Daily Hormone Study (DHS) of the Study of Women's Health Across the Nation (SWAN) included 848 women aged 43-53 yr at baseline who collected daily urine for one cycle or up to 50 d annually for 3 yr. MAIN OUTCOME MEASURES: LH, FSH, estrone conjugates, and pregnanediol glucuronide levels were assessed. Cycles were classified by presumed luteal (ovulatory) status and bleeding. Hormones were related to time in study, age, menopausal status, and selected variables. RESULTS: Ovulatory-appearing cycles declined from 80.9% at baseline to 64.7% by the third assessment (H3). Cycles presumed anovulatory and not ending with bleeding by 50 d (anovulatory/nonbleeding) increased from 8.4 to 24% by H3 and were associated with progress to early perimenopause [odds ratio (OR) = 2.66; confidence interval (CI) = 1.17-6.04] or late perimenopause (OR = 56.21; CI = 18.79-168.12; P < 0.0001), African-American ethnicity (OR = 1.91; CI = 1.06-3.43), and less than high school education (OR = 3.51; CI = 1.62-7.62). Anovulatory cycles ending with bleeding remained at about 10% from baseline to H3; compared with ovulatory cycles, they were associated with obesity (OR = 4.68; CI = 1.33-16.52) and more than high school education (OR = 2.12; CI = 1.22-3.69; P = 0.02). Serum estradiol in both the highest and lowest categories was associated with anovulatory/nonbleeding collections. Pregnanediol glucuronide decreased 6.6% for each year on study. Insulin sensitivity measures did not relate strongly to menstrual cycle hormones. CONCLUSIONS: Anovulation without bleeding represents progression of the MT. A small but detectable decrease in luteal progesterone excretion occurs as women progress through the MT.
Authors: Beverley Balkau; Marie-Aline Charles; Thomas Drivsholm; Knut Borch-Johnsen; Nick Wareham; John S Yudkin; Richard Morris; Ivana Zavaroni; Rob van Dam; Edith Feskins; Rafael Gabriel; Malmö Diet; Peter Nilsson; Bo Hedblad Journal: Diabetes Metab Date: 2002-11 Impact factor: 6.041
Authors: John F Randolph; MaryFran Sowers; Ellen B Gold; Beth A Mohr; Judith Luborsky; Nanette Santoro; Daniel S McConnell; Joel S Finkelstein; Stanley G Korenman; Karen A Matthews; Barbara Sternfeld; Bill L Lasley Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: H G Burger; E C Dudley; J L Hopper; N Groome; J R Guthrie; A Green; L Dennerstein Journal: J Clin Endocrinol Metab Date: 1999-11 Impact factor: 5.958
Authors: John F Randolph; MaryFran Sowers; Irina V Bondarenko; Siobán D Harlow; Judith L Luborsky; Roderick J Little Journal: J Clin Endocrinol Metab Date: 2004-04 Impact factor: 5.958
Authors: N Santoro; S L Crawford; J E Allsworth; E B Gold; G A Greendale; S Korenman; B L Lasley; D McConnell; P McGaffigan; R Midgely; M Schocken; M Sowers; G Weiss Journal: Am J Physiol Endocrinol Metab Date: 2002-11-19 Impact factor: 4.310
Authors: Nanette Santoro; Bill Lasley; Dan McConnell; Jenifer Allsworth; Sybil Crawford; Ellen B Gold; Joel S Finkelstein; Gail A Greendale; Jenny Kelsey; Stan Korenman; Judith L Luborsky; Karen Matthews; Rees Midgley; Lynda Powell; Janice Sabatine; Miriam Schocken; Mary Fran Sowers; Gerson Weiss Journal: J Clin Endocrinol Metab Date: 2004-06 Impact factor: 5.958
Authors: Wendy K Marsh; Joyce T Bromberger; Sybil L Crawford; Katherine Leung; Howard M Kravitz; John F Randolph; Hadine Joffe; Claudio N Soares Journal: Menopause Date: 2017-12 Impact factor: 2.953
Authors: Hannah M Atkins; Cynthia J Willson; Marnie Silverstein; Matthew Jorgensen; Edison Floyd; Jay R Kaplan; Susan E Appt Journal: Comp Med Date: 2014-02 Impact factor: 0.982